Zhang Siqi, Cui Hannan, Wang Jing, Zhou Jie, Chen Hongli, Wang Xinli, Yang Qian, Cao Jiahao, Hao Kaili, Fu Shanshan, Zhang Wuyang, Wang Xu, Lin Xinsen, Sun Xiqing, Lei Wei, Wang Tengjiao, Feng Yafei
Department of Orthopedics, Xijing Hospital, The Fourth Military Medical University, Xi'an, 710032, China.
Frontiers Science Center for Flexible Electronics (FSCFE), Xi'an Institute of Flexible Electronics (IFE) & Xi'an Institute of Biomedical Materials and Engineering (IBME), Northwestern Polytechnical University (NPU), 127 West Youyi Road, Xi'an, Shaanxi, 710072, China.
Bioact Mater. 2025 May 14;51:257-273. doi: 10.1016/j.bioactmat.2025.05.007. eCollection 2025 Sep.
Impaired fracture healing in type 2 diabetes mellitus (T2DM) poses a significant clinical challenge, primarily due to a compromised bone microenvironment driven by senescent macrophages and their amplifying effects. Reduced hydrogen sulfide (HS) levels are a critical contributor to this pathology. To address this, we developed HydroWrap, an advanced HS-delivery controller designed to modulate distinct stages of macrophage senescence. Under near-infrared (NIR) irradiation, HydroWrap underwent an increase in temperature, causing the hydrogel network to contract and accelerate HS generation. This rapid delivery restores HS levels, alleviating mitochondrial dysfunction and suppressing senescence-associated secretory phenotypes (SASP), thereby interrupting the senescence cascade. In T2DM's hyperglycemic bone microenvironment, HydroWrap provides sustained, glucose-responsive HS release, promoting mitophagy and preventing macrophage senescence progression. This dual mechanism addresses both acute and chronic dysfunctions associated with senescence. studies demonstrated that HydroWrap significantly improved fracture healing by reducing recovery time and enhancing bone quality. These findings underscore the therapeutic potential of modulating macrophage senescence in T2DM using a biocompatible drug delivery system. HydroWrap offers a promising strategy for improving fracture outcomes in diabetic patients and may hold broader applications in senescence-related diseases.
2型糖尿病(T2DM)中骨折愈合受损构成了重大的临床挑战,主要是由于衰老巨噬细胞驱动的骨微环境受损及其放大效应。硫化氢(HS)水平降低是这一病理过程的关键因素。为了解决这个问题,我们开发了HydroWrap,这是一种先进的HS递送控制器,旨在调节巨噬细胞衰老的不同阶段。在近红外(NIR)照射下,HydroWrap温度升高,导致水凝胶网络收缩并加速HS生成。这种快速递送恢复了HS水平,减轻了线粒体功能障碍并抑制了衰老相关分泌表型(SASP),从而中断了衰老级联反应。在T2DM的高血糖骨微环境中,HydroWrap提供持续的、葡萄糖响应性的HS释放,促进线粒体自噬并防止巨噬细胞衰老进展。这种双重机制解决了与衰老相关的急性和慢性功能障碍。研究表明,HydroWrap通过缩短恢复时间和提高骨质量显著改善了骨折愈合。这些发现强调了使用生物相容性药物递送系统调节T2DM中巨噬细胞衰老的治疗潜力。HydroWrap为改善糖尿病患者的骨折结局提供了一种有前景的策略,并且可能在衰老相关疾病中具有更广泛的应用。